We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMCOS
Collagen Solutions PLC
19 November 2019
19 November 2019
Collagen Solutions plc
("Collagen Solutions" or the "Company")
Investor results presentation
Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces it will hold an investor results briefing on Tuesday, 3 December 2019.
The Company will announce its interim results for the six months ending 30 September 2019 on 3 December 2019 and will provide an update to investors that day. A briefing will take place at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW at 4.30pm for a 4.45pm start.
Jamal Rushdy, CEO and Hilary Spence, CFO will give an overview of the results and the Company's future plans for growth. This will be followed by drinks and a chance to network.
To register, please call 020 7933 8780 or email collagen@walbrookpr.com.
Collagen Solutions Plc Jamal Rushdy, CEO Via Walbrook Hilary Spence, CFO Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRAEVLFFKFFEFBX
(END) Dow Jones Newswires
November 19, 2019 02:01 ET (07:01 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
